$1 million more for prostate research

Researchers at the UC Davis Cancer Center this spring received three new grants totaling more than $1 million to study the genetics of prostate cancer.

Ralph deVere White, director of the UC Davis Cancer Center, received a three-year grant of $468,000 from the National Cancer Institute to study the functions of different p53 mutations in prostate cancer. P53 is a tumor suppresser gene that plays a key role in many cancers.

Christopher Evans, an assistant professor in the Department of Urology, received a two-year grant of $235,000 from the Department of Defense to study p53 mutations in archival prostate cancer tissue.

Paul Gumerlock, an assistant professor in the Division of Hematology/Oncology, received a two-year $425,000 grant from the Department of Defense to study protein interaction with the N-terminus of the androgen receptor.

Prostate cancer research at UC Davis receives $2.5 million of the more than $9 million earmarked for cancer research.

"These grants bolster the UC Davis Cancer Center's efforts to strengthen its work in basic research," said deVere White, a professor and chair of the Department of Urology. "They emphasize that we are joining the national effort to find better ways to detect, treat and ultimately cure cancer."

Home | Table of Contents | To our Readers | Building on Basics
Focusing on Patients | In Translation | First Steps
Campus Connection | Benefactors | News in Brief

UC Davis Health System | © 2000, 2001, 2002 UC Regents. All rights reserved.

Pathologist Edward Larkin discusses how flow cytometry can be used to diagnose hematologic malignancies. A professor in the medical school's pathology department, Larkin was one of more than a dozen presenters and more than 90 scientists who attended the program.